On the stock market since 2019, it operates in the world of health and science. It has 220 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $52.8M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 27 buys and 6 sells. Management buying with its own money is usually read as a good sign.
A loss of $11.2M against $52.8M in annual sales.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 33/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, APYX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: APYX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.